Philadelphia College of Osteopathic Medicine Internal Medicine

Topics

• Cancer Immunotherapy and Biomarkers 52
• Lung Cancer Treatments and Mutations 33
• Lung Cancer Research Studies 15
• Innovations in Medical Education 13
• CAR-T cell therapy research 11
• Autoimmune and Inflammatory Disorders Research 10
• Lung Cancer Diagnosis and Treatment 9
• Intracranial Aneurysms: Treatment and Complications 7
• Dementia and Cognitive Impairment Research 6
• Lymphoma Diagnosis and Treatment 6
• Regulation of Appetite and Obesity 6
• Rheumatoid Arthritis Research and Therapies 6

Most cited

1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

   The New England journal of medicine · 2021 · 1,513 citations · Hossein Borghaei

2. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

   The New England journal of medicine · 2023 · 479 citations · Hossein Borghaei

3. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 381 citations · Hossein Borghaei

4. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 561 citations · Hossein Borghaei

5. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 288 citations · Hossein Borghaei

6. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.

   Lancet (London, England) · 2025 · 82 citations · Hossein Borghaei

7. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

   Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022 · 272 citations · Hossein Borghaei

8. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 99 citations · Hossein Borghaei